![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RS Chang, VJ Lotti, TB Chen and KA Kunkel
[3H]-(+/-)-L-364,718 a new, potent and selective nonpeptide peripheral cholecystokinin (CCK) antagonist bound saturably and reversibly to rat pancreatic membranes. The radioligand recognized a single class of binding sites with a high affinity (Kd = 0.23 nM). The binding of [3H]- (+/-)-L-364,718 was stereospecific in that the more biologically active (-)-enantiomer demonstrated greater potency than the (+)-enantiomer. The rank order of potency of various CCK agonists and antagonists in displacing [3H]-(+/-)-L-364,718 correlated with their ability to displace [125I]CCK-8 and their known pharmacological activities in peripheral tissues. However, the absolute potencies of agonists were greater in displacing [125I]CCK-8 than [3H]-(+/-)-L-364,718. As described for other physiologically relevant receptor systems, the potency for displacement of [3H]-(+/-)-L-364,718 binding by CCK agonists, but not antagonists, was reduced by guanosine 5'-(beta, gamma- imido)triphosphate and NaCl and enhanced by MgCl2. [3H]-(+/-)-L-364,718 also demonstrated specific binding to bovine gall bladder tissue but not guinea pig brain or gastric glands, consistent with its selectivity as a peripheral CCK antagonist. [3H]-(+/-)-L-364,718 binding to pancreatic membranes was not affected by various pharmacological agents known to interact with other common peptide and nonpeptide receptor systems. These data indicate that [3H]-(+/-)-L-364,718 represents a new potent nonpeptide antagonist radioligand for the study of peripheral CCK receptors which may allow differentiation of agonist and antagonist interactions.
This article has been cited by other articles:
|
|
 |
|
  X.-Q. Ding, D. I. Pinon, K. E. Furse, T. P. Lybrand, and L. J. Miller Refinement of the Conformation of a Critical Region of Charge-Charge Interaction between Cholecystokinin and Its Receptor Mol. Pharmacol., May 1, 2002; 61(5): 1041 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamazaki, W. E. Neway, T. Ohe, I-W. Chen, J. F. Rowe, J. H. Hochman, M. Chiba, and J. H. Lin In Vitro Substrate Identification Studies for P-glycoprotein-Mediated Transport: Species Difference and Predictability of in Vivo Results J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 723 - 735. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors Pharmacol. Rev., December 1, 1999; 51(4): 745 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Roettger, D. Ghanekar, R. Rao, C. Toledo, J. Yingling, D. Pinon, and L. J. Miller Antagonist-Stimulated Internalization of the G Protein-Coupled Cholecystokinin Receptor Mol. Pharmacol., March 1, 1997; 51(3): 357 - 362. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
